瑞德西韦通过共价修饰有效抑制羧酸酯酶-2：表明存在强烈的药物相互作用。
Remdesivir potently inhibits carboxylesterase-2 through covalent modifications: signifying strong drug-drug interactions.
作者信息
Shen Yue, Eades William, Yan Bingfang
机构信息
Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA.
出版信息
Fundam Clin Pharmacol. 2021 Apr;35(2):432-434. doi: 10.1111/fcp.12643. Epub 2021 Jan 6.
Abstract
Remdesivir was recently approved to treat COVID-19. While this antiviral agent delivers clinical benefits, several safety concerns in many cases have been raised. This study reports that remdesivir at nanomolar concentrations inhibits carboxylesterase-2 (CES2) through covalent modifications. CES2 is a major drug-metabolizing enzyme. The combination of high potency with irreversible inhibition concludes that cautions must be exercised when remdesivir is used along with drugs hydrolyzed by CES2.
摘要
瑞德西韦最近被批准用于治疗新冠肺炎。虽然这种抗病毒药物带来了临床益处，但在许多情况下也引发了一些安全问题。本研究报告称，纳摩尔浓度的瑞德西韦通过共价修饰抑制羧酸酯酶-2（CES2）。CES2是一种主要的药物代谢酶。高效力与不可逆抑制的结合表明，当瑞德西韦与由CES2水解的药物联合使用时必须谨慎。
相似文献
1
Remdesivir potently inhibits carboxylesterase-2 through covalent modifications: signifying strong drug-drug interactions.瑞德西韦通过共价修饰有效抑制羧酸酯酶-2：表明存在强烈的药物相互作用。
Fundam Clin Pharmacol. 2021 Apr;35(2):432-434. doi: 10.1111/fcp.12643. Epub 2021 Jan 6.
2
Remdesivir (Veklury) for COVID-19.用于治疗新冠肺炎的瑞德西韦（Veklury）
Med Lett Drugs Ther. 2020 Nov 30;62(1612):186-188.
3
Safety profile of the antiviral drug remdesivir: An update.抗病毒药物瑞德西韦的安全性概况：最新情况
Biomed Pharmacother. 2020 Oct;130:110532. doi: 10.1016/j.biopha.2020.110532. Epub 2020 Jul 22.
4
What Do We Know About Remdesivir Drug Interactions?我们对瑞德西韦的药物相互作用了解多少？
Clin Transl Sci. 2020 Sep;13(5):842-844. doi: 10.1111/cts.12815. Epub 2020 Jun 26.
5
COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19.2019冠状病毒病最新情况：瑞德西韦（Veklury）用于高危2019冠状病毒病门诊患者。
Med Lett Drugs Ther. 2022 Feb 21;64(1644):31-32.
6
Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance.瑞德西韦（GS-5734）在 COVID-19 治疗中的第四次机会。
Curr Drug Targets. 2021;22(12):1346-1356. doi: 10.2174/1389450121999201202110303.
7
Remdesivir for patients with COVID-19.瑞德西韦用于治疗新冠肺炎患者。
CMAJ. 2021 Jan 25;193(4):E125. doi: 10.1503/cmaj.202505. Epub 2021 Jan 6.
8
Remdesivir for the treatment of COVID-19 in pregnancy.瑞德西韦用于治疗妊娠期新型冠状病毒肺炎
J Med Virol. 2021 Jul;93(7):4114-4119. doi: 10.1002/jmv.26986. Epub 2021 Apr 14.
9
Remdesivir as a broad-spectrum antiviral drug against COVID-19.瑞德西韦作为一种广谱抗 COVID-19 病毒药物。
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):541-548. doi: 10.26355/eurrev_202101_24426.
10
Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1).瑞德西韦是否应用于治疗 COVID-19 患者？美国医师学会的快速实践要点（第 1 版）。
Ann Intern Med. 2021 Feb;174(2):229-236. doi: 10.7326/M20-5831. Epub 2020 Oct 5.
引用本文的文献
1
Carboxylesterase Factors Influencing the Therapeutic Activity of Common Antiviral Medications Used for SARS-CoV-2 Infection.影响用于新型冠状病毒感染的常见抗病毒药物治疗活性的羧酸酯酶因素。
Pharmaceutics. 2025 Jun 26;17(7):832. doi: 10.3390/pharmaceutics17070832.
2
Metabolism Pathways of Major Therapeutics for Treating Monkeypox Mono- and Co-infection with Human Immunodeficient Virus or SARS-CoV-2.治疗猴痘病毒与人免疫缺陷病毒或 SARS-CoV-2 单重和双重感染的主要治疗药物的代谢途径。
Curr Drug Metab. 2023;24(4):240-249. doi: 10.2174/1389200224666230607124102.
3
Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir.基于病毒靶点和代谢的原理，联合使用最近获得授权的小分子 COVID-19 药物：莫努匹韦、奈玛特韦和瑞德西韦。
Fundam Clin Pharmacol. 2023 Aug;37(4):726-738. doi: 10.1111/fcp.12889. Epub 2023 Mar 25.
4
Covalent CES2 Inhibitors Protect against Reduced Formation of Intestinal Organoids by the Anticancer Drug Irinotecan.共价CES2抑制剂可防止抗癌药物伊立替康导致肠道类器官形成减少。
Curr Drug Metab. 2022;23(12):1000-1010. doi: 10.2174/1389200224666221212143904.
5
Effect of alcohol exposure on the efficacy and safety of tenofovir alafenamide fumarate, a major medicine against human immunodeficiency virus.酒精暴露对富马酸替诺福韦艾拉酚胺酯（一种主要的抗人类免疫缺陷病毒药物）疗效和安全性的影响。
Biochem Pharmacol. 2022 Oct;204:115224. doi: 10.1016/j.bcp.2022.115224. Epub 2022 Aug 22.
6
The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro.COVID-19 口服药物莫努匹韦是 CES2 的底物：潜在的药物-药物相互作用和 CES2 遗传多态性的体外影响。
Drug Metab Dispos. 2022 Sep;50(9):1151-1160. doi: 10.1124/dmd.122.000918. Epub 2022 Jul 5.
7
Development and validation of a paper spray mass spectrometry method for the rapid quantitation of remdesivir and its active metabolite, GS-441524, in human plasma.一种用于快速定量人血浆中瑞德西韦及其活性代谢物GS-441524的纸喷雾质谱法的开发与验证
J Mass Spectrom Adv Clin Lab. 2022 Aug;25:27-35. doi: 10.1016/j.jmsacl.2022.06.001. Epub 2022 Jun 11.
8
The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance.核苷类抗病毒前药瑞德西韦在治疗新型冠状病毒肺炎及其他疾病中的种间意义。
Anim Dis. 2021;1(1):15. doi: 10.1186/s44149-021-00017-5. Epub 2021 Sep 7.
9
Injectable niclosamide nanohybrid as an anti-SARS-CoV-2 strategy.可注射的尼氯硝唑纳米杂化体作为一种抗 SARS-CoV-2 的策略。
Colloids Surf B Biointerfaces. 2021 Dec;208:112063. doi: 10.1016/j.colsurfb.2021.112063. Epub 2021 Aug 24.
10
Human carboxylesterases and fluorescent probes to image their activity in live cells.人类羧酸酯酶及用于在活细胞中成像其活性的荧光探针。
RSC Med Chem. 2021 May 18;12(7):1142-1153. doi: 10.1039/d1md00073j. eCollection 2021 Jul 21.
本文引用的文献
1
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
2
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
3
Compassionate Use of Remdesivir for Patients with Severe Covid-19.瑞德西韦在治疗重症 COVID-19 患者中的同情使用。
N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10.
4
Covalent inhibition of carboxylesterase-2 by sofosbuvir and its effect on the hydrolytic activation of tenofovir disoproxil.索磷布韦对羧酸酯酶-2的共价抑制作用及其对替诺福韦酯水解活化的影响。
J Hepatol. 2017 Mar;66(3):660-661. doi: 10.1016/j.jhep.2016.11.025. Epub 2016 Dec 10.
5
Carboxylesterase-2 is a highly sensitive target of the antiobesity agent orlistat with profound implications in the activation of anticancer prodrugs.羧酸酯酶 2 是一种高度敏感的抗肥胖药物奥利司他的作用靶点，对激活抗癌前药具有深远意义。
Biochem Pharmacol. 2013 Feb 1;85(3):439-47. doi: 10.1016/j.bcp.2012.11.026. Epub 2012 Dec 7.
Zotero 插件